Pfizer And BioNTech Claim COVID-19 Vaccine Success
Interim Analysis Finds Vaccine 90% Effective, EUA Filing Expected Late November
The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.
